Overview

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Status:
Not yet recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected pancreatic adenocarcinoma.

Phase:

Early Phase 1

Details

Lead Sponsor:

Fudan University

Collaborator:

Shanghai Regenelead Therapies Co., Ltd.